Latest treatment of lung cancer Stories
Data Supportive of GEN-2, an RNAi Carrier for Therapeutic Treatment of Lung Cancer LAWRENCEVILLE, N.J., Oct.
VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB:
ORCA(TM) program includes seven Phase 2 trials in tumor types where patient need is acute, including bladder, lung, pancreas and prostate cancers BOTHELL, Wash.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or
Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals,
A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
U.S. Preventive Services Task Force Recommends Screening for those at High Risk of Lung Cancer ST. LOUIS, Jan.
Full Coverage and Reimbursement for CT Screening Next Priority WASHINGTON, Dec.